# US 2016/0250215 A1 · Quinazoline compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250215 A1
- Document ID: US20160250215A1
- Status: Published application
- Kind: A1
- Application number: 14/998,042
- Filed: 2015-12-23
- Published: 2016-09-01
- Earliest claimed: 2014-12-24
- Assignees: Gilead Sciences, Inc.; Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
- Applicants: Gilead Sciences, Inc.; Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i.
- Inventors: Ondrej BASZCZYNSKI; Milan DEJMEK; Yunfeng Eric HU; Petr JANSA; Eric LANSDON; Richard L. MACKMAN; Petr SIMON
- Web page: https://patentgrep.com/patent/US20160250215A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/84: Nitrogen atoms
- C07D 239/94: Nitrogen atoms
- C07D 239/95: with hetero atoms directly attached in positions 2 and 4
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

## Claims

### Claim 1

A compound of formula (I):
wherein
Q is
X1, X2, and X3 are each independently N or C(R11), provided that, at most 2 of X1, X2, and X3 are N;
R1 is —H, —CN, —ORa, —C(O)ORa, halogen, C1-6alkyl, C3-10cycloalkyl, or C1-6heteroalkyl, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R2 is —H, —CN, —ORa, —NRaRb, —C(O)ORa, halogen, C1-6alkyl, C3-10cycloalkyl, or C1-6 heteroalkyl, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R3 is —H, —ORa, —SRa, —NRaRb, —NHC(O)NRaRb, C1-6alkyl, C3-10cycloalkyl, or C1-6 heteroalkyl, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R4 is —H, —ORa, halogen, —NO2, —CN, —NRaRb, —NHC(O)NRaRb, —OC(O)NRaRb, —CH2C(O)NRaRb, C1-6alkyl, C3-10cycloalkyl, or C1-6 heteroalkyl, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R5 is —H, —ORa, halogen, —NO2, —CN, —NRaRb, —NHC(O)NRaRb, —OC(O)NRaRb, —CH2C(O)NRaRb, C1-6alkyl, C3-10cycloalkyl, or C1-6heteroalkyl, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R6 is —H, —ORa, halogen, —NO2, —CN, —NRaRb, —NHC(O)NRaRb, —OC(O)NRaRb, —CH2C(O)NRaRb, C1-6alkyl, C3-10cycloalkyl, or C1-6heteroalkyl, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R7 is C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, halogen, —ORa, —CN, or —NO2, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R8 is C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, halogen, —ORa, —CN, or —NO2, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R9 is —H, C1-6alkyl, or C3-10cycloalkyl, wherein each C1-6alkyl and C3-10cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
R10 is —H, C1-6alkyl, or C3-10cycloalkyl, wherein each C1-6alkyl and C3-10cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
each R11 is independently —H, —CN, —ORa, —C(O)ORa, halogen, C1-6alkyl, C3-10cycloalkyl, or C1-6heteroalkyl, which may be same or different, wherein each C1-6alkyl, C3-10cycloalkyl, and C1-6heteroalkyl is optionally substituted with 1, 2, 3, 4, or 5 R12 groups, which may be same or different;
each R12 is independently C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, 5-10 membered heterocyclyl, C6-10aryl, 5-10 membered heteroaryl, halogen, —ORa, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —OC(O)NRaRb, —NRaC(O)ORb, —SRa, —S(O)1-2Ra, —S(O)2F, —S(O)2NRaRb, —NRaS(O)2Rb, —N3, —CN, or —NO2; wherein each C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, and 5-10 membered heterocyclyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halogen, —ORa, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —OC(O)NRaRb, —NRaC(O)ORb, —SRa, —S(O)1-2Ra, —S(O)2F, —S(O)2NRaRb, —NRaS(O)2Rb, —N3, —CN, and —NO2, groups, which may be same or different;
each Ra and Rb is independently —H, —NH2, C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, 5-10 membered heterocyclyl, C6-10aryl, or 5-10 membered heteroaryl, wherein each C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, 5-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 R13 groups, which may be same or different; or Ra and Rb together with the atoms to which they are attached form a 5-10 membered heterocycle; and
each R13 is independently —CN, halogen, C1-6alkyl, C3-10cycloalkyl, C1-6heteroalkyl, or 5-10 membered heterocyclyl,
or a tautomer or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R2 is —H, —CN, —ORa, or C1-6alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R2 is —CN.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Q is

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein X1, X2, and X3 are each CH.

### Claim 8 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein X1 is N; X2 is CH; and X3 is CH.

### Claim 9 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein X1, X2, and X3 are C(R11); each R11 are independently selected from —H, —CN, —ORa, halogen, and C1-6alkyl; and R1 is selected from —H, —CN, —ORa, halogen, and C1-6alkyl.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R3 is —H, —ORa, —NRaRb, —NHC(O)NRaRb, C1-6alkyl, or C1-6heteroalkyl.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R3 is —NH2 or —OH.

### Claim at position 14

14-18. (canceled)

### Claim 19 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein two of R4, R5, and R6 are —H and one of R4, R5, and R6 is —H, —ORa, halogen, —NO2, —CN, —NRaRb, —NHC(O)NRaRb, or C1-6alkyl.

### Claim at position 16

20-21. (canceled)

### Claim 22 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R4, R5, and R6 are —H.

### Claim 23 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R7 is C1-6alkyl, C1-6heteroalkyl, halogen, —ORa, —CN, or —NO2.

### Claim 24 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R8 is C1-6alkyl, C1-6heteroalkyl, halogen, —ORa, —CN, or —NO2.

### Claim at position 20

25-26. (canceled)

### Claim 27 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are C1-6alkyl.

### Claim 28 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are methyl.

### Claim 29 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R9 is —H or C1-6alkyl.

### Claim 30 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein R10 is —H or C1-6alkyl.

### Claim at position 25

31-32. (canceled)

### Claim 33 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, Q is selected from

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A compound of claim 1, wherein the compound is selected from the group consisting of:
Structure
Compound ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

### Claim at position 29

36-37. (canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, further comprising one, two, three, or four additional therapeutic agents.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the therapeutic agent is independently selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof.

### Claim at position 33

41-43. (canceled)

### Claim 44 (depends on 1)

A method for treating an HIV infection in a subject comprising administering to the subject a compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 1)

A method for treating an HIV infection in a subject comprising administering to the subject in need thereof a compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating or preventing HIV, and combinations thereof.

### Claim at position 36

46-51. (canceled)
